JP6255349B2 - 慢性疼痛軽減に用いるための経粘膜薬物送達デバイス - Google Patents

慢性疼痛軽減に用いるための経粘膜薬物送達デバイス Download PDF

Info

Publication number
JP6255349B2
JP6255349B2 JP2014548962A JP2014548962A JP6255349B2 JP 6255349 B2 JP6255349 B2 JP 6255349B2 JP 2014548962 A JP2014548962 A JP 2014548962A JP 2014548962 A JP2014548962 A JP 2014548962A JP 6255349 B2 JP6255349 B2 JP 6255349B2
Authority
JP
Japan
Prior art keywords
mucoadhesive
drug delivery
delivery device
buprenorphine
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014548962A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015500886A (ja
JP2015500886A5 (ko
Inventor
フィン，アンドリュー
ヴァシシュト，ニラジ
Original Assignee
バイオデリバリー サイエンシズ インターナショナル，インコーポレーテッド
バイオデリバリー サイエンシズ インターナショナル，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオデリバリー サイエンシズ インターナショナル，インコーポレーテッド, バイオデリバリー サイエンシズ インターナショナル，インコーポレーテッド filed Critical バイオデリバリー サイエンシズ インターナショナル，インコーポレーテッド
Publication of JP2015500886A publication Critical patent/JP2015500886A/ja
Publication of JP2015500886A5 publication Critical patent/JP2015500886A5/ja
Application granted granted Critical
Publication of JP6255349B2 publication Critical patent/JP6255349B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
JP2014548962A 2011-12-21 2012-12-21 慢性疼痛軽減に用いるための経粘膜薬物送達デバイス Active JP6255349B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161578755P 2011-12-21 2011-12-21
US61/578,755 2011-12-21
PCT/US2012/071330 WO2013096811A2 (en) 2011-12-21 2012-12-21 Transmucosal drug delivery devices for use in chronic pain relief

Publications (3)

Publication Number Publication Date
JP2015500886A JP2015500886A (ja) 2015-01-08
JP2015500886A5 JP2015500886A5 (ko) 2016-02-04
JP6255349B2 true JP6255349B2 (ja) 2017-12-27

Family

ID=48669710

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014548962A Active JP6255349B2 (ja) 2011-12-21 2012-12-21 慢性疼痛軽減に用いるための経粘膜薬物送達デバイス

Country Status (16)

Country Link
EP (1) EP2793870A4 (ko)
JP (1) JP6255349B2 (ko)
KR (4) KR20190110628A (ko)
CN (2) CN110123792A (ko)
AU (4) AU2012358308A1 (ko)
BR (1) BR112014015329A8 (ko)
CA (1) CA2859859A1 (ko)
EA (2) EA201992762A1 (ko)
HK (1) HK1203365A1 (ko)
IL (2) IL233075A0 (ko)
IN (1) IN2014DN06117A (ko)
MX (2) MX362217B (ko)
SG (3) SG10201710667YA (ko)
UA (1) UA118540C2 (ko)
WO (1) WO2013096811A2 (ko)
ZA (1) ZA201804381B (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021163529A2 (en) * 2020-02-13 2021-08-19 Biodelivery Sciences International, Inc. Methods of treatment with buprenorphine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800832A (en) 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
DE19652188C2 (de) * 1996-12-16 2002-02-14 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur Applikation und Freisetzung von Buprenorphin oder einer pharmakologisch vergleichbaren Substanz in der Mundhöhle und Verfahren zu ihrer Herstellung
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19960154A1 (de) * 1999-12-14 2001-07-12 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur transmucosalen Verabreichung von Oxycodon oder einem vergleichbaren Wirkstoff in der Mundhöhle, für die Anwendung in der Schmerztherapie und Suchttherapie
CN1423559A (zh) * 2000-02-08 2003-06-11 欧罗赛铁克股份有限公司 包含阿片样激动剂和拮抗剂的控释组合物
EP1389621A4 (en) 2001-04-27 2005-05-11 Ajinomoto Kk N-SUBSTITUTED PYRAZOLYL-O-GLYCOSIDE DERIVATIVES AND DIABETES CONTAINING THEREOF
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
DE102005007859A1 (de) * 2005-02-21 2006-08-24 Lts Lohmann Therapie-Systeme Ag Vefahren für eine medikamentöse Kombinations-Behandlung, sowie hierfür geeignete Arzneimittel-Kombinationen
US20060281775A1 (en) * 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
BRPI0619806A2 (pt) 2005-12-13 2011-10-18 Biodelivery Sciences Int Inc dispositivo para fornecimento de fármacos transmucosal resistente ao abuso
CA2649107A1 (en) 2006-04-12 2007-10-25 Spinal Motion, Inc. Posterior spinal device and method
KR101329496B1 (ko) * 2006-07-21 2013-11-13 바이오딜리버리 사이언시스 인터내셔널 인코포레이티드 향상된 흡수를 갖는 경점막 전달 장치
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
GB0620661D0 (en) * 2006-10-18 2006-11-29 Pharmasol Ltd Novel compounds
US20090270438A1 (en) * 2006-10-18 2009-10-29 Clive Booles Novel compositions and formulations
GB2447016A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
CN105833420A (zh) * 2008-06-23 2016-08-10 生物递送科学国际公司 多向粘膜给药装置及使用方法
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions

Also Published As

Publication number Publication date
KR20220047889A (ko) 2022-04-19
JP2015500886A (ja) 2015-01-08
UA118540C2 (uk) 2019-02-11
HK1203365A1 (en) 2015-10-30
IN2014DN06117A (ko) 2015-08-14
EA201992762A1 (ru) 2020-07-31
MX2014007350A (es) 2014-09-15
SG11201403075XA (en) 2014-07-30
KR102026321B1 (ko) 2019-09-27
MX2021012154A (es) 2021-11-03
AU2019202602A1 (en) 2019-05-02
AU2017258916A1 (en) 2017-11-30
AU2021202042A1 (en) 2021-04-29
CN110123792A (zh) 2019-08-16
BR112014015329A2 (pt) 2017-06-13
IL233075A0 (en) 2014-07-31
AU2012358308A1 (en) 2014-07-24
ZA201804381B (en) 2022-12-21
SG10202012743WA (en) 2021-01-28
MX362217B (es) 2019-01-09
CA2859859A1 (en) 2013-06-27
AU2017258916B2 (en) 2019-01-17
WO2013096811A3 (en) 2014-07-24
KR20140106720A (ko) 2014-09-03
EP2793870A2 (en) 2014-10-29
CN104125828A (zh) 2014-10-29
EA201491046A1 (ru) 2014-11-28
EA034529B1 (ru) 2020-02-18
KR20210003313A (ko) 2021-01-11
KR20190110628A (ko) 2019-09-30
WO2013096811A2 (en) 2013-06-27
IL285091A (en) 2021-08-31
EP2793870A4 (en) 2016-02-17
SG10201710667YA (en) 2018-02-27
BR112014015329A8 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
JP6657454B2 (ja) ブプレノルフィンの乱用抵抗性粘膜付着性送達デバイス
US20240148639A1 (en) Transmucosal drug delivery devices for use in chronic pain relief
JP6255349B2 (ja) 慢性疼痛軽減に用いるための経粘膜薬物送達デバイス
US20240130961A1 (en) Transmucosal drug delivery devices for use in chronic pain relief
US20210251983A1 (en) Methods of treatment with buprenorphine
NZ724912B2 (en) Transmucosal drug delivery devices for use in chronic pain relief

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170516

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171003

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171204

R150 Certificate of patent or registration of utility model

Ref document number: 6255349

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250